Sun Chemical and its parent company, DIC Corporation, have entered into a definitive agreement to acquire 100 percent of the shares of Sensient Imaging Technologies and certain other assets related to the production of inks. The transaction is expected to be finalized in the second quarter of 2020.
Sun Chemical will increase the prices of its solvent-based inks and coatings in North America, effective July 1, 2020.
Three new companies were approved to join the growing membership of the Society of Chemical Manufacturers & Affiliates (SOCMA) by its Board of Governors last week. The addition of Advanced Chemical Concepts (ACC), Revtech and Texas Molecular brings the total number of new members to 11 in the first five months of the year.
COVID-19 Resources for the Specialty Chemical Industry SOCMA continues to monitor the impacts of COVID-19 on business continuity related to... View Article
OSHA has issued two revised guidance memos on recordkeeping and enforcement in response to the COVID-19 pandemic. On May 26, 2020, the previous memos from April on these topics will be rescinded, and the new memos will go into and remain in effect until further notice.
CJB Applied Technologies, LLC is pleased to announce James
M. Loar ("Jim") has joined the company as Chief Commercial Officer, where he will lead global commercial activities related to innovation, contract development and manufacturing.
Internationally respected demographer, Ken Gronbach, stated the U.S. economy would not suffer as a result of COVID-19 because of it's position in the global landscape.
In this post, SOCMA shares the following core considerations for developing return to work plans. The following information was compiled based on information shared during a SOCMA roundtable with DanChem, Strem Chemicals, Inc and Sun Chemical Corporation. A template return to work plan is in development and will be available in the coming week.
Customer letter from Advanced Chemical Concepts to address COVID-19 challenges.
Moderna, Inc. and Lonza Ltd. today announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna's mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.